- Trials with a EudraCT protocol (90)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
90 result(s) found for: Immunophenotyping.
Displaying page 1 of 5.
EudraCT Number: 2020-000419-56 | Sponsor Protocol Number: TCD601B101 | Start Date*: 2021-03-23 | |||||||||||
Sponsor Name:ITB-MED AB | |||||||||||||
Full Title: A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (si... | |||||||||||||
Medical condition: renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016966-97 | Sponsor Protocol Number: CAD01 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ... | |||||||||||||
Medical condition: Cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002085-31 | Sponsor Protocol Number: RAD-ON02 | Start Date*: 2017-11-14 |
Sponsor Name:Kurort Forschungsverein Bad Steben e.V. | ||
Full Title: Determining the immunological and pain reducing effects of serial radon balneology in patients with musculoskeletal disorders. | ||
Medical condition: Chronic degenerative spine and/or joint disorders with pain perception of at least 1 year and pain intensity on visual analogue scale ≥4 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004835-30 | Sponsor Protocol Number: CAD5 | Start Date*: 2012-10-23 |
Sponsor Name:Department of Medicine, Haugesund Hospital | ||
Full Title: Therapy for chronic cold agglutinin disease: A prospective, non-randomized international multicenter trial on the safety and efficacy of bendamustine and rituximab combination therapy. | ||
Medical condition: Primary chronic cold agglutinin disease requiring treatment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004879-46 | Sponsor Protocol Number: RG_16-123 | Start Date*: 2017-06-15 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL) | |||||||||||||
Medical condition: Relapsed and refractory T-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003563-36 | Sponsor Protocol Number: ACQUIVAS | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge | |||||||||||||
Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV) | |||||||||||||
Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000998-31 | Sponsor Protocol Number: APHP220267 | Start Date*: 2023-03-10 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra. | |||||||||||||
Medical condition: Patients with a non resectable HCC registered on national waiting list for LT with no complete response to TACE as a bridging loco-regional treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001992-17 | Sponsor Protocol Number: APHP210369 | Start Date*: 2021-08-16 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux de Paris / DRCI | |||||||||||||
Full Title: Isatuximab in type I cryoglobulinaemia: A prospective pilot study / ICE STUDY | |||||||||||||
Medical condition: Type I cryoglobulinemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001949-20 | Sponsor Protocol Number: 1.0 | Start Date*: 2023-01-09 | |||||||||||
Sponsor Name:ALBIMMUNE S.L. | |||||||||||||
Full Title: Human albumin treatment in adult septic shock. A phase 2, multicenter, randomized, controlled study evaluating the immune response and organ failure. | |||||||||||||
Medical condition: Septic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001753-17 | Sponsor Protocol Number: ATYR1940-C-002 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:aTyr Pharma, Inc. | |||||||||||||
Full Title: A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Define... | |||||||||||||
Medical condition: Facioscapulohumeral muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001029-14 | Sponsor Protocol Number: P150949J | Start Date*: 2018-10-25 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic... | |||||||||||||
Medical condition: SCID pediatric patients (n=12 for analysis) requiring an HLA partially compatible allogeneic HSCT. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001748-36 | Sponsor Protocol Number: GCT3013-01 | Start Date*: 2018-09-24 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma | |||||||||||||
Medical condition: Relapsed, progressive and/or refractory mature B-cell lymphoma Patients with: - Diffuse large B-cell lymphoma – de novo or transformed - High-grade B-cell lymphoma - Primary mediastinal large B... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002988-25 | Sponsor Protocol Number: ML-DS2018 | Start Date*: Information not available in EudraCT |
Sponsor Name:Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH) | ||
Full Title: Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 | ||
Medical condition: Myeloid Leukemia in Children with Down Syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NL (Ongoing) AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000933-37 | Sponsor Protocol Number: CRT113890 | Start Date*: 2012-09-18 |
Sponsor Name:National and Kapodostrian University of Athens | ||
Full Title: Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previ... | ||
Medical condition: Relapsed or refractory diffuse large B cell lymphoma (DLBCL). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011587-11 | Sponsor Protocol Number: RHMCAN0658 | Start Date*: 2010-02-11 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: INVESTIGATING THE CLINICAL USE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PREVENAR)IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA | ||
Medical condition: Childhood Acute Lymphoblastic Leukaemia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000505-39 | Sponsor Protocol Number: CHUBX2014/13 | Start Date*: 2015-03-19 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: The role of dexchlorpheniramine (Polaramine®) to prevent hemodynamic instability after separation from cardiopulmonary bypass during cardiac surgery. | |||||||||||||
Medical condition: vasoplegic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000183-65 | Sponsor Protocol Number: TTCC-2022-01-RADIAN | Start Date*: 2023-08-23 | |||||||||||
Sponsor Name:Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC) | |||||||||||||
Full Title: Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN) | |||||||||||||
Medical condition: Locally-Advanced head and Neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003833-21 | Sponsor Protocol Number: TJT2301 | Start Date*: 2023-04-04 |
Sponsor Name:CHU of Liège | ||
Full Title: Is local injection of mesenchymal stem cells after endoscopic dilation safe and does it improve the outcome of intestinal stricture in patients with Crohn's disease? | ||
Medical condition: Crohn's disease patients with symptomatic intestinal stricture eligible to endoscopic dilatation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003151-11 | Sponsor Protocol Number: ECD-TCZ-1-03/2012 | Start Date*: 2012-09-27 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO | |||||||||||||
Full Title: An open-label, single-arm, phase II, prospective, pilot study of tocilizumab in patients with Erdheim-Chester disease. | |||||||||||||
Medical condition: Erdheim Chester patology | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001571-32 | Sponsor Protocol Number: APHP200406 | Start Date*: 2020-04-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris | ||
Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
